Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting.
Future Oncol
; 18(3): 301-309, 2022 Jan.
Article
en En
| MEDLINE
| ID: mdl-34709061
Lay abstract Since its first approval in 2015, daratumumab has become the backbone of many multiple myeloma treatment regimens. While its approval has improved outcomes in many patients who undergo treatment, it is expensive and has largely contributed to the increasing costs of care in multiple myeloma. In its most common treatment schedule, patients should transition from weekly and biweekly dosing to treatment once every 4 weeks. However, many providers maintain their patients on a more frequent dosing schedule, which increases Medicare 1-year costs by an estimated US$31,353 and may have unforeseen impacts on adverse events and patient outcomes.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Costos y Análisis de Costo
/
Utilización de Medicamentos
/
Anticuerpos Monoclonales
/
Mieloma Múltiple
Tipo de estudio:
Health_economic_evaluation
/
Observational_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Future Oncol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos